Fortress Biotech Inc Cash Flow Conversion Efficiency
Fortress Biotech Inc cash flow conversion efficiency. Based on the latest financial reports, Fortress Biotech Inc (FBIO) has a cash flow conversion efficiency ratio of -0.202x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.54 Million) by net assets ($62.18 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Fortress Biotech Inc (2009–2025)
Cash flow conversion efficiency of Fortress Biotech Inc from 2009 to 2025. This chart illustrates how Fortress Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Fortress Biotech Inc for real-time trading data and today's change.
Fortress Biotech Inc Cash Flow Conversion Ratio Explained
Fortress Biotech Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Fortress Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Fortress Biotech Inc ranked by their cash flow conversion efficiency. Also see FBIO market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
0.034x |
|
Endava plc
F:2Y5
|
0.050x |
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
-0.200x |
|
Santierul Naval Orsova SA
RO:SNO
|
0.009x |
|
Akoya Biosciences Inc
NASDAQ:AKYA
|
1.225x |
|
Macroblock
TWO:3527
|
-0.014x |
|
Sun Brothers Development Co Ltd
TWO:3489
|
-0.122x |
|
Stillwater Critical Minerals Corp
V:PGE
|
-0.113x |
Annual Cash Flow Conversion Efficiency for Fortress Biotech Inc (2009–2025)
The table below shows the annual cash flow conversion efficiency of Fortress Biotech Inc from 2009 to 2025. Review Fortress Biotech Inc (FBIO) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $62.18 Million | $-65.78 Million | -1.058x | -102.17% |
| 2024-12-31 | $-1.64 Million | $-80.19 Million | 48.778x | +160.37% |
| 2023-12-31 | $1.59 Million | $-128.22 Million | -80.797x | -2152.98% |
| 2022-12-31 | $50.02 Million | $-179.40 Million | -3.586x | -595.08% |
| 2021-12-31 | $225.88 Million | $-116.54 Million | -0.516x | -21.46% |
| 2020-12-31 | $197.00 Million | $-83.68 Million | -0.425x | +67.55% |
| 2019-12-31 | $72.53 Million | $-94.96 Million | -1.309x | +73.85% |
| 2018-12-31 | $19.74 Million | $-98.85 Million | -5.007x | -606.22% |
| 2017-12-31 | $120.50 Million | $-85.43 Million | -0.709x | -28.39% |
| 2016-12-31 | $82.97 Million | $-45.81 Million | -0.552x | -128.35% |
| 2015-12-31 | $84.27 Million | $-20.38 Million | -0.242x | -4.40% |
| 2014-12-31 | $70.52 Million | $-16.33 Million | -0.232x | +36.50% |
| 2013-12-31 | $81.28 Million | $-29.65 Million | -0.365x | +65.35% |
| 2012-12-31 | $22.03 Million | $-23.19 Million | -1.053x | -83.89% |
| 2011-12-31 | $19.13 Million | $-10.95 Million | -0.572x | -34.92% |
| 2010-12-31 | $13.38 Million | $-5.68 Million | -0.424x | -282.10% |
| 2009-12-31 | $-10.09 Million | $-2.35 Million | 0.233x | -- |
About Fortress Biotech Inc
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalc… Read more